$DNAI 2.07 0.05 +2.48 1,048,671 Day High
Post# of 22756
Posted On: 06/23/2016 9:55:25 PM
$DNAI 2.07 0.05 +2.48 1,048,671
Day High 2.13
Day Low 1.9801
52 Week High 7/16/2015 | 33.75
52 Week Low 6/14/2016 | 1.86
Shares Outstanding 30.18M
Float 29.2M
Company Background
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer. The Company's PNT2258 is a formulation of its single-stranded 24-base DNAi oligonucleotide, known as PNT100, encapsulated in the SMARTICLES Lipid Nanoparticle (LNP). The Company's PNT2258 consists of over two components, including PNT100 DNAi Oligonucleotide and LNP Delivery Technology. It has conducted over two clinical trials for PNT2258, which include a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
http://pronai.com/
Day High 2.13
Day Low 1.9801
52 Week High 7/16/2015 | 33.75
52 Week Low 6/14/2016 | 1.86
Shares Outstanding 30.18M
Float 29.2M
Company Background
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer. The Company's PNT2258 is a formulation of its single-stranded 24-base DNAi oligonucleotide, known as PNT100, encapsulated in the SMARTICLES Lipid Nanoparticle (LNP). The Company's PNT2258 consists of over two components, including PNT100 DNAi Oligonucleotide and LNP Delivery Technology. It has conducted over two clinical trials for PNT2258, which include a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
http://pronai.com/
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼